A phase 1b randomized, open, positive control clinical trial to evaluate tolerability, pharmacokinetics and pharmacodynamics of muti-dose of HS-10234 in HBV-infected subjects

Trial Profile

A phase 1b randomized, open, positive control clinical trial to evaluate tolerability, pharmacokinetics and pharmacodynamics of muti-dose of HS-10234 in HBV-infected subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2017

At a glance

  • Drugs HS 10234 (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Shanghai Hansen Biomedical Technology
  • Most Recent Events

    • 25 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top